DRUG · Mapped RxNorm record
Paclitaxel
Normalized identity: paclitaxelView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
NCT03716180
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Trastuzumab
Normalized identity: trastuzumabView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Pertuzumab
Normalized identity: pertuzumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedDAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
PaclitaxelDRUG · verified · RxNorm: paclitaxel
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PertuzumabDRUG · verified · RxNorm: pertuzumab
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Susan G. Komen Breast Cancer Foundationcollaborator
Breast Cancer Research Foundationcollaborator
Terri Brodeur Breast Cancer Foundationcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03716180 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.